Joshua K. Sabari, MD

Articles

Treatment Options for Patients with NSCLC with EGFR Mutations

August 29th 2023

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Strategies to Improve Biomarker Testing in NSCLC

August 29th 2023

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Biomarker Testing Patterns in Academic and Community Settings Treating NSCLC

August 22nd 2023

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

NSCLC: Biomarker Testing Strategies and Turnaround Time

August 22nd 2023

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Liquid vs Tissue Biopsies in NSCLC

August 15th 2023

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

Biomarker Testing in Non-Small Cell Lung Cancer

August 15th 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

Dr Sabari on Preliminary Data From a Phase 1 Study of LY3537982 in KRAS G12C–mutant Advanced Solid Tumors

April 17th 2023

Joshua K. Sabari, MD, discusses key findings from the phase 1 LOXO-RAS-20001 study of the KRAS G12C inhibitor LY3537982 in KRAS G12C–mutant advanced solid tumors.

KRAS G12C–Mutated NSCLC: Real-World Implications of Novel Targeted Therapy

December 30th 2022

Closing out their review of treatment options for KRAS G12C–mutated NSCLC, expert oncologists look toward future utilization of novel targeted agents in this setting.

2L KRAS Inhibitors for Patients With KRAS G12C–Mutated NSCLC

December 30th 2022

Centering discussion on KRAS inhibitors and associated clinical trials, Martin Dietrich, MD, PhD, and Joshua Sabari, MD, detail the second-line management of KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Selecting 1L Therapy for Patients With KRAS G12C Mutations

December 23rd 2022

Key opinion leaders identify the first-line treatment armamentarium for patients with KRAS G12C–mutated non–small cell lung cancer.

Non–Small Cell Lung Cancer: Informing 1L Therapy Selection With Molecular Testing

December 23rd 2022

A brief review of how results from adequate molecular testing may help to inform the first-line management of non–small cell lung cancer.

Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

December 23rd 2022

Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.

Emerging Strategies for the Management of NSCLC With KRAS/STK11/KEAP1 Mutations

December 16th 2022

Shared perspectives on the emerging strategies for the management of non–small cell lung cancer following the identification of KRAS/STK11, or KRAS/KEAP1 mutations.

Overcoming Barriers to Molecular Testing in Non–Small Cell Lung Cancer

December 16th 2022

A comprehensive discussion on how to overcome barriers that may inhibit access to adequate molecular testing in patients with non–small cell lung cancer.

Selecting Optimal Treatment for NSCLC With KRAS/STK11, or KRAS/KEAP1 Mutations

December 16th 2022

Contextualizing treatment selection with the POSEIDEN and CheckMate 9LA clinical trials, experts consider how to select the optimal treatment for patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated NSCLC.

Addressing Inadequate Molecular Testing in Patients With NSCLC

December 16th 2022

Expert perspectives on course-correcting the management of patients with NSCLC who may not have received adequate molecular profiling in the past.

Dr. Sabari on the Importance of Timely Testing for Uncommon Mutations in NSCLC

December 9th 2022

Joshua K. Sabari, MD, discusses the importance of timely testing for uncommon mutations in non–small cell lung cancer.

Non–Small Cell Lung Cancer: Optimizing the Identification of KRAS G12C Mutations

December 9th 2022

Shared insight on best practices in non–small cell lung cancer management to utilize molecular testing and identify patients harboring KRAS G12C mutations.

POSEIDON Study Post-hoc Analysis: Outcomes in Patients With KRAS/STK11/KEAP1 Mutations

December 9th 2022

A focused review of data from the POSEIDEN post-hoc analysis in patients with concomitant KRAS/STK11, or KRAS/KEAP1–mutated non–small cell lung cancer.

Understanding the Nature of a KRAS G12C Mutation in NSCLC

December 9th 2022

Expert oncologists Martin Dietrich, MD, PhD, and Joshua Sabari, MD, elucidate the emergence of KRAS G12C as a molecular marker in the setting of non–small cell lung cancer.